This is an excerpt from the Scottish Medicines Consortium (SMC) advice on etravirine (Intelence).
ADVICE: following a full submission
etravirine (Intelence), in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is not recommended for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients.
In HIV-1 infected adults with resistance to currently available non-nucleoside reverse transcriptase inhibitors (NNRTIs) and at least three primary protease inhibitor (PI) mutations who were receiving an optimized background regimen that included boosted darunavir, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and optional enfuvirtide, etravirine produced significant improvements in virological, immunological and clinical outcomes when compared with placebo.
The manufacturer’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC.
The license holder has indicated their intention to resubmit.
Related: Etravirine (Intelence) review from Health Canada
